Acquiring Negotiation Rights for the Co-Selling of a Treatment for Refractory Chronic Cough
First written in FY2020-Q1. 4 of 6 entries say "Advanced", first in FY2022-Q1. Latest entry: FY2024-Q1.
No other company in this theme has enough history to compare yet.
- FY2024-Q1AdvancedAnnual report
「The cough treatment Lyfnua, for which prescription-duration restrictions were lifted in May 2023, also contributed to the increase in sales.」
For Lyfnua, the lifting of prescription-duration restrictions in May 2023 was followed by a contribution to higher sales. - FY2023-Q1AdvancedAnnual report
「For Lyfnua, a selective P2X3 receptor antagonist and cough treatment newly launched in April 2022, the Company provided information mainly to respiratory specialists to promote understanding of the product's characteristics.」
Following the acquisition of the exclusive domestic marketing rights for a chronic cough treatment, progress was made through the launch of Lyfnua in April 2022 and the provision of information to specialists. - FY2022-Q3AdvancedAnnual report
「In domestic and overseas development during the third quarter of the fiscal year, MSD, the originator of the selective P2X3 receptor antagonist and cough treatment Rifanua Tablets 45 mg, with gefapixant citrate as its generic name, obtained marketing approval. Kyorin Pharmaceutical Co., Ltd. had entered into an agreement to acquire exclusive marketing rights in Japan for the product.」
For the chronic cough treatment, the arrangement progressed from negotiation rights for co-promotion and the acquisition of exclusive sales rights in Japan to the originator obtaining marketing approval. - FY2022-Q2RestatedAnnual report
「In April of the same year, the company entered into an agreement under which Kyorin Pharmaceutical Co., Ltd. would obtain exclusive sales rights in Japan for gefapixant citrate, a chronic cough treatment for which MSD was seeking marketing approval.」
The company continues to state that, for the chronic cough treatment, the arrangement progressed from a memorandum of understanding on negotiation rights for co-promotion to an agreement granting exclusive sales rights in Japan. - FY2022-Q1AdvancedAnnual report
「In April of the same year, the company entered into an agreement under which Kyorin Pharmaceutical Co., Ltd. would obtain exclusive sales rights in Japan for gefapixant citrate, a chronic cough treatment for which MSD was seeking marketing approval.」
For the chronic cough treatment, the arrangement progressed from a memorandum of understanding on negotiation rights for co-promotion to an agreement granting exclusive sales rights in Japan. - FY2020-Q1First statedAnnual report
「Memorandum of understanding concerning negotiation rights for the co-selling of a treatment for refractory chronic cough under development by MSD Co., Ltd.」
In 2019, a memorandum of understanding was signed with respect to negotiation rights for co-selling an MSD treatment for refractory chronic cough.